Janssen (J&J) Signs an Exclusive WW Research Collaboration with Morphic to Develop Human Integrins Therapies

Shots:

• Morphic to receive upfront, $725M milestones, and royalties on WW sales of products. Janssen to get exclusive option to license integrin therapies post IND submission and will fund the clinical trials
• If the option is exercised, Janssen to get exclusive WW development and commercialization rights of the products
• Morphic’s Integrins are receptors present on human cells responsible for cell survival, cell cycle progression, cell differentiation, and cell migration focusing on fibrosis, autoimmune diseases, and immuno-oncology

Click here to read full press release/ article | Ref: Morphic Therapeutics | Image: News Pharmaceutical